Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christodoulos Papadopoulos

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
European Journal of Heart Failure|January 6, 2022
Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'Michael Doumas, Dimitrios Patoulias, Christodoulos Papadopoulos
International Journal of Cardiology|December 2, 2021
Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Indian Heart Journal|March 14, 2021
Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysisDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Kardiologia Polska|March 29, 2021
Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology|April 23, 2022
Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos
The American Journal of Cardiology|April 6, 2022
Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure IndicesDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos
Internal and Emergency Medicine|March 25, 2022
"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" commentDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology|March 9, 2022
Meta-Analysis Addressing the Cardiovascular Safety of Daprodustat in Patients With Chronic Kidney Disease Undergoing Dialysis or NotDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
European Journal of Internal Medicine|February 26, 2021
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fractionDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Polish Archives of Internal Medicine|December 23, 2021
Sodium-glucose cotransporter 2 inhibitors and heart failure decompensation: considerations on body composition and skeletal massDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
European Journal of Heart Failure|January 6, 2022
Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'Michael Doumas, Dimitrios Patoulias, Christodoulos Papadopoulos
International Journal of Cardiology|December 2, 2021
Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Indian Heart Journal|March 14, 2021
Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysisDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Kardiologia Polska|March 29, 2021
Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology|April 23, 2022
Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes MellitusDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos
The American Journal of Cardiology|April 6, 2022
Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure IndicesDimitrios Patoulias, Michael Doumas, Christodoulos Papadopoulos
Internal and Emergency Medicine|March 25, 2022
"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" commentDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology|March 9, 2022
Meta-Analysis Addressing the Cardiovascular Safety of Daprodustat in Patients With Chronic Kidney Disease Undergoing Dialysis or NotDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
European Journal of Internal Medicine|February 26, 2021
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fractionDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Polish Archives of Internal Medicine|December 23, 2021
Sodium-glucose cotransporter 2 inhibitors and heart failure decompensation: considerations on body composition and skeletal massDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Pageof 13